Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen.
about
Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cellsSub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancerModulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic miceRole of autoreactive CD8+ T cells in organ-specific autoimmune diseases: insight from transgenic mouse models.Autoaggression and tumor rejection: it takes more than self-specific T-cell activation.Changes in function of antigen-specific lymphocytes correlating with progression towards diabetes in a transgenic model.Expression level of a pancreatic neo-antigen in beta cells determines degree of diabetes pathogenesis.64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET.DNA vaccination: transfection and activation of dendritic cells as key events for immunity.Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance.Triggering a second T cell receptor on diabetogenic T cells can prevent induction of diabetes.Conditions that induce tolerance in mature CD4+ T cellsSelf antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapyCross-tolerance: a pathway for inducing tolerance to peripheral tissue antigensAbortive proliferation of rare T cells induced by direct or indirect antigen presentation by rare B cells in vivo.Antagonist peptide selects thymocytes expressing a class II major histocompatibility complex-restricted T cell receptor into the CD8 lineageOntogeny of T cell tolerance to peripherally expressed antigens.CD4 T cell tolerance to human C-reactive protein, an inducible serum protein, is mediated by medullary thymic epithelium.The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells.Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.Expression of a second receptor rescues self-specific T cells from thymic deletion and allows activation of autoreactive effector function.Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires.Aberrant expression of tissue-specific proteins in the thymus: a hypothesis for the development of central tolerance.Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.T-helper-1-cell cytokines drive cancer into senescence.Infectious Th1 and Th2 autoimmunity in diabetes-prone mice.De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors.The Ii41 isoform of invariant chain mediates both positive and negative selection events in T-cell receptor transgenic mice.Induction of peripheral CD8+ T-cell tolerance by cross-presentation of self antigens
P2860
Q24653129-445678ED-0FC0-46BF-B6A2-C35E8681025DQ24793123-6D3844EC-6847-4015-A6DB-4D69BF81450EQ28770154-C9F1F15A-3D38-40F8-9E83-EEB5A6BE98AFQ33713291-4110763C-D5B2-40F9-B637-85229BAD5D83Q33713362-EFFF4EDC-A6D5-464D-A406-1A90AC959A7FQ33887966-542F5E6A-1D61-435B-B5D6-06035BE0ABA0Q34238702-44C86178-1DF3-4430-8E61-2D1D1541A596Q34458153-03FE8FC8-16D3-4C74-B924-28E8B0086947Q35834601-9AC19026-276A-4F1B-BE51-4ED81A86423FQ36369913-CD51759F-6954-420E-AD00-A39587DAB632Q36375231-DCBA99ED-D0A1-459D-8085-3ED72AE3F266Q36376510-E00B852E-D406-4378-B1A9-FE0961558EEEQ36380506-6219E6BB-9607-406E-BBA5-2A234939438AQ36400803-8C50B5DE-6F93-4329-867B-60A03876E5D1Q36400871-28D4561F-FFB1-42CD-A25D-B7A1257FE932Q36401775-13A006AA-1A36-4B47-9C86-A446FE6A9BAEQ36453129-35DDE809-A85E-427A-B143-F6DE5CC07E4BQ36851767-2755209D-9A47-4E3C-AEB7-FDF0CD0336A5Q36882243-8B368981-CEAA-47BA-B768-7577CAA73AFCQ37319028-213F407D-F65E-43E9-A1CB-FC7104C5B907Q37385909-9B4E0BD9-5955-4527-965B-C60EC8F1410AQ37689611-36A0BC01-34D8-4312-9FE4-9A5FF9A0E2E1Q41718895-36AC6A33-507B-4E95-86DA-E02ABEB37774Q43108657-AB9051B1-36DA-4495-A5BF-74F703FBC77CQ44539245-B823F456-1DAD-4D81-AEDE-B060FF1C1F8FQ45983475-C8BC2AB8-5413-4DE0-BA14-04AABCFE0425Q47822985-9DE5F094-3272-41C8-A26F-FF9A809C50ECQ54662060-599B762C-1EE6-4C2A-B2F8-10ACD97110D0Q57228016-A1BC4B78-5EBB-4169-B28A-46EB2B46AE1C
P2860
Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Limited capacity for tolerizat ...... creatic beta cell neo-antigen.
@en
type
label
Limited capacity for tolerizat ...... creatic beta cell neo-antigen.
@en
prefLabel
Limited capacity for tolerizat ...... creatic beta cell neo-antigen.
@en
P2093
P1433
P1476
Limited capacity for tolerizat ...... ncreatic beta cell neo-antigen
@en
P2093
P304
P356
10.1016/1074-7613(95)90002-0
P407
P577
1995-06-01T00:00:00Z